Praxis Precision Medicines, Inc. financial data

Symbol
PRAX on Nasdaq
Industry
Pharmaceutical Preparations
Location
99 High Street, 30 Th Floor, Boston, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05K % +165%
Debt-to-equity 10.1 % -73.3%
Return On Equity -61.5 % +65.6%
Return On Assets -55.9 % +56.9%
Operating Margin -7.49K % +30.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.8M shares -86.2%
Common Stock, Shares, Outstanding 17.8M shares -86.2%
Entity Public Float 147M USD +42%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 18.8M shares +305%
Weighted Average Number of Shares Outstanding, Diluted 18.8M shares +305%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.77M USD +21%
Research and Development Expense 89.9M USD -18.2%
General and Administrative Expense 44.6M USD -11.5%
Operating Income (Loss) -133M USD +16.4%
Nonoperating Income (Expense) 8.96M USD +369%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.9M USD +1.69%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -124M USD +21.1%
Earnings Per Share, Basic -5.31 USD/shares +93.7%
Earnings Per Share, Diluted -5.31 USD/shares +93.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 145M USD +16.8%
Cash, Cash Equivalents, and Short-term Investments 434M USD
Assets, Current 357M USD +175%
Property, Plant and Equipment, Net 369K USD -51.4%
Operating Lease, Right-of-Use Asset 1.61M USD -35.4%
Other Assets, Noncurrent 416K USD 0%
Assets 441M USD +230%
Accounts Payable, Current 8.2M USD +2.31%
Accrued Liabilities, Current 10.1M USD -24.5%
Contract with Customer, Liability, Current 1.18M USD -42.3%
Liabilities, Current 20.6M USD -15.6%
Contract with Customer, Liability, Noncurrent 588K USD -60.7%
Operating Lease, Liability, Noncurrent 755K USD -61.2%
Liabilities 22M USD -21.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -71K USD
Retained Earnings (Accumulated Deficit) -726M USD -20.5%
Stockholders' Equity Attributable to Parent 419M USD +297%
Liabilities and Equity 441M USD +230%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD +36.5%
Net Cash Provided by (Used in) Financing Activities 183M USD +911%
Net Cash Provided by (Used in) Investing Activities -91.2M USD -368%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 17.8M shares -86.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 70.7M USD +268%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146M USD +16.7%
Deferred Tax Assets, Valuation Allowance 181M USD +25.4%
Deferred Tax Assets, Gross 181M USD +25.2%
Operating Lease, Liability 2.5M USD -28.7%
Depreciation 112K USD +5.66%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -124M USD +20.7%
Lessee, Operating Lease, Liability, to be Paid 2.73M USD -31.8%
Property, Plant and Equipment, Gross 1.59M USD +3.24%
Operating Lease, Liability, Current 1.19M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32M USD +1.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.3M USD +2.05%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD -53.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 110K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 74.5M USD +24.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 110K USD -91.7%
Additional Paid in Capital 1.15B USD +61.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 559K USD -24.9%
Share-based Payment Arrangement, Expense 31.8M USD +20.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%